Analysts think CRMD stock price could increase by 10%
Jun 07, 2025, 11:25 AM
-16.82%
What does CRMD do
CorMedix is a pharmaceutical company based in New Jersey, focused on developing therapeutic products, notably DefenCath, an antimicrobial solution for preventing catheter-related bloodstream infections in kidney failure patients. The company went public in 2010 and has also sponsored research on taurolidine for rare pediatric tumors.
7 analysts think CRMD stock price will increase by 9.52%. The current median analyst target is $15.30 compared to a current stock price of $13.97. The lowest analysts target is $13.13 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
